SEC Form S-8 filed by Orchestra BioMed Holdings Inc.
As filed with the Securities and Exchange Commission on February 19, 2025
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
ORCHESTRA BIOMED HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
Delaware | 92-2038755 | |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) |
150 Union Square Drive
New Hope, Pennsylvania 18928
(Address of Principal Executive Offices) (Zip Code)
Orchestra BioMed Holdings, Inc. 2023 Equity Incentive Plan
(Full titles of the plans)
David P. Hochman
Chief Executive Officer
150 Union Square Drive
New Hope, PA 18928
(215) 862-5797
(Name, address and telephone number, including area code, of agent for service)
Copies to:
Yariv Katz, Esq.
Keith Pisani, Esq.
Paul Hastings LLP
200 Park Avenue
New York, NY 10016
(212) 318-6000
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ¨ | Accelerated filer | ¨ |
Non-accelerated filer | x | Smaller reporting company | x |
Emerging growth company | x |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨
EXPLANATORY NOTE; INCORPORATION BY REFERENCE
OF CONTENTS OF
REGISTRATION STATEMENTS ON FORM S-8
Pursuant to General Instruction E of Form S-8, Orchestra BioMed Holdings, Inc. (the “Registrant” or the “Company”) is filing this Registration Statement with the Securities and Exchange Commission (the “SEC”) to register 1,833,333 additional shares of common stock, par value $0.0001 per share (“Common Stock”), of the Registrant reserved for issuance under the Orchestra BioMed Holdings, Inc. 2023 Equity Incentive Plan (the “2023 Plan”) resulting from an automatic annual increase as of January 1, 2025. This Registration Statement hereby incorporates by reference the contents of the Registrant’s previous Registration Statements on Form S-8 filed with the SEC on April 3, 2023 (File No. 333-271092) and March 27, 2024 (File No. 333-278285).
PART I
INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
The information called for in Part I of Form S-8 is not being filed with or included in this Form S-8 (by incorporation by reference or otherwise) in accordance with the rules and regulations of the SEC.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
ITEM 3. | INCORPORATION OF DOCUMENTS BY REFERENCE. |
The following documents filed by the Registrant with the SEC are hereby incorporated by reference into this Registration Statement:
(a) | The Registrant’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 27, 2024; |
(b) | The Registrant’s Quarterly Reports on Form 10-Q for the quarter ended March 31, 2024, filed with the SEC on May 13, 2024, for the quarter ended June 30, 2024, filed with the SEC on August 12, 2024, and for the quarter ended September 30, 2024, filed with the SEC on November 12, 2024; |
(c) | The Registrant’s Current Reports on Form 8-K, filed with SEC on March 29, 2024, June 20, 2024, July 30, 2024 (excluding the information furnished under Item 7.01), August 12, 2024 and February 5, 2025 (excluding the information furnished under Item 7.01); and |
(d) | The description of the Registrant’s Common Stock contained in Exhibit 4.16 to the Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 27, 2024, including any amendment or reports filed for the purpose of updating such description. |
All other reports and other documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part of this Registration Statement from the date of the filing of such reports and documents, except as to any portion of any future current report furnished under Items 2.02 or 7.01 of Form 8-K that is not deemed filed under such provisions.
For the purposes of this Registration Statement, any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
2
You should rely only on the information provided or incorporated by reference in this Registration Statement or any related prospectus. The Registrant has not authorized anyone to provide you with different information. You should not assume that the information in this Registration Statement or any related prospectus is accurate as of any date other than the date on the front of the document.
You may contact the Registrant in writing or orally to request copies of the above-referenced filings, without charge (excluding exhibits to such documents unless such exhibits are specifically incorporated by reference into the information incorporated into this Registration Statement). Requests for such information should be directed to:
Orchestra BioMed Holdings, Inc.
150 Union Square Drive
New Hope, PA 18938
Attn: Chief Executive Officer
ITEM 8. EXHIBITS.
* | Filed herewith. |
3
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in city of New York, State of New York, on February 19, 2025.
ORCHESTRA BIOMED HOLDINGS, INC. | ||
By: | /s/ David P. Hochman | |
Name: | David P. Hochman | |
Title: | Chief Executive Officer |
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints David P. Hochman and Andrew L. Taylor, and each or any one of them, as his or her true and lawful attorneys-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
SIGNATURE | TITLE | DATE | ||
/s/ David P. Hochman | Chief Executive Officer, Chairperson and Director | February 19, 2025 | ||
David P. Hochman | (Principal Executive Officer) | |||
/s/ Andrew L. Taylor | Chief Financial Officer | February 19, 2025 | ||
Andrew L. Taylor | (Principal Financial Officer) | |||
/s/ Joshua Aiello | Corporate Controller | February 19, 2025 | ||
Joshua Aiello | (Principal Accounting Officer) | |||
/s/ Jason Aryeh | Director | February 19, 2025 | ||
Jason Aryeh | ||||
/s/ Chris Cleary | Director | February 19, 2025 | ||
Chris Cleary | ||||
/s/ Pamela A. Connealy | Director | February 19, 2025 | ||
Pamela A. Connealy | ||||
/s/ Eric S. Fain, M.D. | Director | February 19, 2025 | ||
Eric S. Fain, M.D. | ||||
/s/ David Pacitti | Director | February 19, 2025 | ||
David Pacitti | ||||
/s/ Darren R. Sherman | Chief Operating Officer and Director | February 19, 2025 | ||
Darren R. Sherman |
4